AKAM
59
-2
VZ
39
2
STX
42
-2
MUR
34
-10
SWKS
53
3
IVZ
50
-5
EMR
64
-3
EXR
48
-3
GT
56
-2
IPG
49
2
ROK
52
-2
CA
25
-7
MAS
52
-2
AN
50
-5
WBA
64
4
EXPD
37
-2
SIG
54
2
WU
28
-4
FOX
68
-2
ALL
41
6
AKAM
59
-2
VZ
39
2
STX
42
-2
MUR
34
-10
SWKS
53
3
IVZ
50
-5
EMR
64
-3
EXR
48
-3
GT
56
-2
IPG
49
2
ROK
52
-2
CA
25
-7
MAS
52
-2
AN
50
-5
WBA
64
4
EXPD
37
-2
SIG
54
2
WU
28
-4
FOX
68
-2
ALL
41
6
Financhill
Back

AbCellera Biologics 10K Form

Buy
60

ABCL
AbCellera Biologics

Last Price:
2.81
Seasonality Move:
-23.52%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2021-03-30 10K ABCL/AbCellera Biologics Annual

Receive ABCL News And Ratings

See the #1 stock for the next 7 days that we like better than ABCL

ABCL Financial Statistics

Sales & Book Value

Annual Sales: $38.03M
Cash Flow: $-47.4M
Price / Cash Flow: 0
Annual Sales: $3.65
Price / Book: 0.77

Profitability

EPS (TTM): -0.61000
Net Income (TTM): $-175.8M
Gross Margin: $38.03M
Return on Equity: -15.55%
Return on Assets: -12.09%

AbCellera Biologics Earnings Forecast

Key AbCellera Biologics Financial Ratios

  • The Gross Profit Margin over the past 6 years for ABCL is 100.00%.
  • The Selling, General & Administrative Expenses for ABCL have been equal to 197.71% of Gross Profit Margin.
  • The Research & Development expenses have been 461.95% of Revenue.
  • The Interest Expense is 2.55% of Operating Income.
  • The Net Earning history of ABCL is -385.00% of Total Revenues.
  • Per Share Earnings over the last 6 years have been positive in 3 years.

AbCellera Biologics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Life Sciences Tools & Services
Sector: Health Care
Current Symbol: ABCL
CUSIP: 00288U
Website: abcellera.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 9.34
Quick Ratio: 8.88

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

ABCL Technical Analysis vs Fundamental Analysis

Buy
60
AbCellera Biologics (ABCL) is a Buy

Is AbCellera Biologics a Buy or a Sell?